Alternative splicing of HER2: a novel mediator of EGFR TKI resistance.

Adam J. Schoenfeld, Joseph M. Chan, Daisuke Kubota, Hiroki Sato, Hira Rizvi, Yahya Daneshbod, Jason C. Chang, Paul K. Paik, Michael Offin, Maria E. Arcila, Monika A. Davare, Ujwal Shinde, Dana Pe'er, Natasha Rekhtman, Mark G. Kris, Romel Somwar, Gregory J. Riely, Marc Ladanyi, Helena A. Yu, Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer Clinical Cancer Research. ,vol. 26, pp. 2654- 2663 ,(2020) , 10.1158/1078-0432.CCR-19-3563

Jacqueline H. Starrett, Alexis A. Guernet, Maria Emanuela Cuomo, Kamrine E. Poels, Iris K. van Alderwerelt van Rosenburgh, Amy Nagelberg, Dylan Farnsworth, Kristin S. Price, Hina Khan, Kumar Dilip Ashtekar, Mmaserame Gaefele, Deborah Ayeni, Tyler F. Stewart, Alexandra Kuhlmann, Susan M. Kaech, Arun M. Unni, Robert Homer, William W. Lockwood, Franziska Michor, Sarah B. Goldberg, Mark A. Lemmon, Paul D. Smith, Darren A.E. Cross, Katerina Politi, Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations. Cancer Research. ,vol. 80, pp. 2017- 2030 ,(2020) , 10.1158/0008-5472.CAN-19-3819

Abdullah Alajati, Nina Sausgruber, Nicola Aceto, Stephan Duss, Sophie Sarret, Hans Voshol, Debora Bonenfant, Mohamed Bentires-Alj, Mammary Tumor Formation and Metastasis Evoked by a HER2 Splice Variant Cancer Research. ,vol. 73, pp. 5320- 5327 ,(2013) , 10.1158/0008-5472.CAN-12-3186

Mark G. Kris, Bruce E. Johnson, Lynne D. Berry, David J. Kwiatkowski, A. John Iafrate, Ignacio I. Wistuba, Marileila Varella-Garcia, Wilbur A. Franklin, Samuel L. Aronson, Pei-Fang Su, Yu Shyr, D. Ross Camidge, Lecia V. Sequist, Bonnie S. Glisson, Fadlo R. Khuri, Edward B. Garon, William Pao, Charles Rudin, Joan Schiller, Eric B. Haura, Mark Socinski, Keisuke Shirai, Heidi Chen, Giuseppe Giaccone, Marc Ladanyi, Kelly Kugler, John D. Minna, Paul A. Bunn, Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs JAMA. ,vol. 311, pp. 1998- 2006 ,(2014) , 10.1001/JAMA.2014.3741

Darren A.E. Cross, Susan E. Ashton, Serban Ghiorghiu, Cath Eberlein, Caroline A. Nebhan, Paula J. Spitzler, Jonathon P. Orme, M. Raymond V. Finlay, Richard A. Ward, Martine J. Mellor, Gareth Hughes, Amar Rahi, Vivien N. Jacobs, Monica Red Brewer, Eiki Ichihara, Jing Sun, Hailing Jin, Peter Ballard, Katherine Al-Kadhimi, Rachel Rowlinson, Teresa Klinowska, Graham H.P. Richmond, Mireille Cantarini, Dong-Wan Kim, Malcolm R. Ranson, William Pao, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer Cancer Discovery. ,vol. 4, pp. 1046- 1061 ,(2014) , 10.1158/2159-8290.CD-14-0337

Y.-L. Wu, C. Zhou, C.-K. Liam, G. Wu, X. Liu, Z. Zhong, S. Lu, Y. Cheng, B. Han, L. Chen, C. Huang, S. Qin, Y. Zhu, H. Pan, H. Liang, E. Li, G. Jiang, S.H. How, M.C.L. Fernando, Y. Zhang, F. Xia, Y. Zuo, First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study Annals of Oncology. ,vol. 26, pp. 1883- 1889 ,(2015) , 10.1093/ANNONC/MDV270

Lorenzo Castagnoli, Manuela Iezzi, Gaia C. Ghedini, Valentina Ciravolo, Giulia Marzano, Alessia Lamolinara, Roberta Zappasodi, Patrizia Gasparini, Manuela Campiglio, Augusto Amici, Claudia Chiodoni, Arianna Palladini, Pier Luigi Lollini, Tiziana Triulzi, Sylvie Menard, Patrizia Nanni, Elda Tagliabue, Serenella M. Pupa, Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab Cancer Research. ,vol. 74, pp. 6248- 6259 ,(2014) , 10.1158/0008-5472.CAN-14-0983

Ken Takezawa, Valentina Pirazzoli, Maria E. Arcila, Caroline A. Nebhan, Xiaoling Song, Elisa de Stanchina, Kadoaki Ohashi, Yelena Y. Janjigian, Paula J. Spitzler, Mary Ann Melnick, Greg J. Riely, Mark G. Kris, Vincent A. Miller, Marc Ladanyi, Katerina Politi, William Pao, HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discovery. ,vol. 2, pp. 922- 933 ,(2012) , 10.1158/2159-8290.CD-12-0108

Bob T. Li, Dara S. Ross, Dara L. Aisner, Jamie E. Chaft, Meier Hsu, Severine L. Kako, Mark G. Kris, Marileila Varella-Garcia, Maria E. Arcila, HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers Journal of Thoracic Oncology. ,vol. 11, pp. 414- 419 ,(2016) , 10.1016/J.JTHO.2015.10.025

Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Melanie A Leiby, Gregory M Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R Brahmer, None, Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 375, pp. 1823- 1833 ,(2016) , 10.1056/NEJMOA1606774